Leerink raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $102 from $88 and keeps an Outperform rating on the shares. The firm is updating its estimates for the company following this morning’s disclosure of bivamelagon Phase 2 data in acquired hypothalamic obesity study that it sees as “close to a best-case scenario”, the analyst tells investors in a research note. Investor feedback has been highly positive on the efficacy, with minimal concerns on safety, the firm added.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals announces $150M common stock offering
- Rhythm Pharmaceuticals price target raised to $95 from $72 at Needham
- Rhythm Pharmaceuticals price target raised to $95 from $73 at BofA
- Rhythm Pharmaceuticals price target raised to $95 from $80 at Morgan Stanley
- Rhythm Pharmaceuticals price target raised to $123 from $94 at Stifel